SCHEMBL3738339

SCHEMBL3738339

C#Cc1nn(Cc2ccc(OC)cc2)c2ncc(C3CC3)c(N3CCN(C(=O)OC(C)(C)C)CC3)c12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
TP53 P04637 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM1A O60341 1/20 0.40
GPR119 Q8TDV5 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
STS P08842 1/20 0.38
HTT P42858 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
CRHBP P24387 1/20 0.37
KMT2A Q03164 1/20 0.37
CRHR2 Q13324 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3743204 0.90 MAPT (0.39) MAPTTP53TDP1LMNASMN1; SMN2
SCHEMBL3727382 0.90 KDM4E (0.37) TP53ALDH1A1L3MBTL1KDM4EHPGD
SCHEMBL3716849 0.90 MAPT (0.43) MAPTTP53TDP1LMNASMN1; SMN2
SCHEMBL3723302 0.88 MAPT (0.42) MAPTTP53TDP1LMNASMN1; SMN2
SCHEMBL3739575 0.88 MAPT (0.42) MAPTTP53TDP1LMNASMN1; SMN2
SCHEMBL3732959 0.87 MAPT (0.41) MAPTTP53TDP1LMNASMN1; SMN2
SCHEMBL3717081 0.83 MAPT (0.46) MAPTTP53TDP1LMNASMN1; SMN2
SCHEMBL3729807 0.81 TDP1 (0.39) MAPTTP53TDP1LMNASMN1; SMN2
SCHEMBL3729810 0.81 TDP1 (0.39) MAPTTP53TDP1LMNASMN1; SMN2
SCHEMBL3731410 0.80 KDM4E (0.34) TP53ALDH1A1L3MBTL1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372842-B2 Pyrazolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-02-12 US disclosed
CN-101965347-B Pyrazolopyridines as kinase inhibitors ARRAY BIOPHARMA INC 2013-01-02 CN disclosed
EP-2242757-B1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2012-08-01 EP disclosed
CN-101965347-A Pyrazolopyridines as kinase inhibitors ARRAY BIOPHARMA INC 2011-02-02 CN disclosed
US-20100280043-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280043-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B MAPT 3636/4885TP53 46/4885TDP1 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.